Cargando…
Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer
Chromosome 17q23 amplification occurs in ~11% of human breast cancers. Enriched in HER2+ breast cancers, the 17q23 amplification is significantly correlated with poor clinical outcomes. In addition to the previously identified oncogene WIP1, we uncover an oncogenic microRNA gene, MIR21, in a majorit...
Autores principales: | Liu, Yunhua, Xu, Jiangsheng, Choi, Hyun Ho, Han, Cecil, Fang, Yuanzhang, Li, Yujing, Van der Jeught, Kevin, Xu, Hanchen, Zhang, Lu, Frieden, Michael, Wang, Lifei, Eyvani, Haniyeh, Sun, Yifan, Zhao, Gang, Zhang, Yuntian, Liu, Sheng, Wan, Jun, Huang, Cheng, Ji, Guang, Lu, Xiongbin, He, Xiaoming, Zhang, Xinna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226492/ https://www.ncbi.nlm.nih.gov/pubmed/30413718 http://dx.doi.org/10.1038/s41467-018-07264-0 |
Ejemplares similares
-
Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II
por: Li, Yujing, et al.
Publicado: (2018) -
An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity
por: Zhou, Zhuolong, et al.
Publicado: (2021) -
Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer
por: Xu, Jiangsheng, et al.
Publicado: (2019) -
Carbon nano-onion-mediated dual targeting of P-selectin and P-glycoprotein to overcome cancer drug resistance
por: Wang, Hai, et al.
Publicado: (2021) -
CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer
por: Sun, Weilin, et al.
Publicado: (2022)